XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
   Small Cell Carcinoma
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Lung Channel
subscribe to Lung newsletter

Latest Research : Cancer : Lung

   DISCUSS   |   EMAIL   |   PRINT
Better Combination Therapy for Patients with Locally Advanced Lung Cancer
Sep 4, 2005, 08:00, Reviewed by: Dr.

“Giving radiation and chemotherapy from day one appears to be the best approach for these patients,”

 
While researchers have learned in the last decade that combining chemotherapy with radiation is better than radiation alone for treating non-small cell lung cancer patients with locally advanced disease – cancer confined to the lungs – finding the right combination of drugs – and the best timing of treatment – has been tricky.

A new study led by lung cancer specialists at Jefferson Medical College adds to growing evidence that giving patients both chemotherapy and radiation in the beginning of treatment may help patients live longer. Non-small-cell lung cancer accounts for about 80 percent of all cases of lung cancer. An estimated 40,000 Americans are diagnosed each year with locally advanced disease.

“This is a further step in looking at what is the best combination of two chemotherapy agents with radiation, which will enable us to move forward and study it more systematically,” says Walter J. Curran Jr., M.D., professor and chair of radiation oncology at Jefferson Medical College at Thomas Jefferson University in Philadelphia and clinical director of Jefferson’s Kimmel Cancer Center, who led the research.

“There are new biologic agents we want to test with chemotherapy, with radiation and with both,” he notes. “Finding the best combination of chemotherapy and radiation provides a template by which we can test these agents.”

The results appear September 1, 2005 in the Journal of Clinical Oncology.

In the multicenter, randomized phase 2 trial, researchers compared three different approaches to treating inoperable non-small-cell lung cancer that had not spread beyond the lungs. They divided more than 250 patients into three treatment arms. One group received chemotherapy before radiation. A second group had chemotherapy before and during radiation. Patients in the third arm received chemotherapy and radiation at the same time, then added a little more chemotherapy after. Each arm had the same schedule of radiation and were given the same two standard chemotherapy agents, carboplatin and paclitaxel.

Dr. Curran and his colleagues found that the patients in the third arm did best, living several months more on average when compared against the standard treatment.

“That’s in keeping with the observed results of other studies,” Dr. Curran says. “Giving radiation and chemotherapy from day one appears to be the best approach for these patients,” though side effects can at first appear to be worse.

“Researchers are already looking at targeted agents such as bevacizumab, cetuximab and other agents with chemotherapy and radiation in lung cancer,” he says. “This kind of study will help guide us as to which schedule to use.”

Some other institutions that participated in the trial include medical centers at the University of Pittsburgh and Vanderbilt University and Rush University Medical Center.
 

- The results appear September 1, 2005 in the Journal of Clinical Oncology.
 

Thomas Jefferson University Hospital

 
Subscribe to Lung Newsletter
E-mail Address:

 



Related Lung News

Gene Expression Profiling Not Quite Perfected in Predicting Lung Cancer Prognosis
I-ELCAP study: Lung cancer can be detected early with annual low-dose CT screening
Key to lung cancer chemotherapy resistance revealed
3D-CRT brings hope for inoperable lung cancers
Sunitinib Malate shows promise against advanced form of lung cancer
Tarceva-Celebrex Combination therapy shows promising results in advanced lung cancer
Lung cancer susceptibility runs in families - Study
Do Variants in the GST Detoxification Genes Affect the Risk of Lung Cancer?
Tumor diameter - an important prognostic indicator for curability
Palliative radiation can cure some NSCLC


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us